CYP2C19*2 Polymorphism is Associated with Increased Survival in Breast Cancer Patients Using Tamoxifen

Pharmacogenomics - Tập 11 Số 10 - Trang 1367-1375 - 2010
Rikje Ruiter1, Monique J. Bijl2, Ron H. N. van Schaik3, Els M.J.J. Berns4, Albert Hofman5, J.W.W. Coebergh6, Charlotte van Noord7, Loes E. Visser8, Bruno HCh Stricker9
1Department of Epidemiology, PO Box 2040, 3000 CA, Rotterdam, The Netherlands and Drug Safety Unit, Inspectorate for Health Care, The Hague, The Netherlands
2Department of Epidemiology, PO Box 2040, 3000 CA, Rotterdam, The Netherlands and Department of Hospital Pharmacy, Rotterdam, The Netherlands
3Department of Clinical Chemistry, Rotterdam, The Netherlands
4Department of Medical Oncology/Josephine Nefkens Institute, Rotterdam, The Netherlands
5Department of Epidemiology, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
6Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
7Department of Epidemiology, PO Box 2040, 3000 CA, Rotterdam, The Netherlands and Dutch Medicines Evaluation Board, The Hague, The Netherlands
8Department of Hospital Pharmacy, Rotterdam, The Netherlands and Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
9Department of Epidemiology, PO Box 2040, 3000 CA, Rotterdam, The Netherlands and Drug Safety Unit, Inspectorate for Health Care, The Hague, The Netherlands and Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands and Department of Medical Informatics, Erasmus MC, Rotterdam, The Netherlands.

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1016/j.ejca.2007.12.015

10.3322/canjclin.55.2.74

10.1016/S0140-6736(05)66544-0

10.1677/joe.0.0750305

10.1023/B:BREA.0000025406.31193.e8

Lien EA , SolheimE, KvinnslandS, UelandPM: Identification of 4-hydroxy-n-desmethyltamoxifen as a metabolite of tamoxifen in human bile.Cancer Res.48(8), 2304–2308 (1988).

10.1007/s00280-004-0926-7

10.1093/carcin/23.11.1897

10.1046/j.1365-2125.2002.01614.x

10.1016/S0006-2952(96)00650-8

10.1124/dmd.30.8.869

Dehal SS , KupferD: CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.Cancer Res.57(16), 3402–3406 (1997).

10.1124/jpet.104.065607

Poon GK , ChuiYC, MccagueR et al.: Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.Drug Metab. Dispos.21(6), 1119–1124 (1993).

10.1093/jnci/dji005

10.1093/jnci/djg108

10.1016/j.clpt.2006.03.013

10.1007/s10549-008-0272-2

10.1007/s10549-006-9428-0

10.1200/JCO.2005.03.3266

10.1200/JCO.2007.12.2705

10.1200/JCO.2009.25.7246

10.1158/1078-0432.CCR-07-5235

10.1007/s10549-009-0328-y

10.1001/jama.2009.1420

10.1158/1078-0432.CCR-08-2006

10.1007/s10549-004-7751-x

10.1186/bcr1640

10.1186/bcr993

10.1002/cncr.24111

10.1016/S1470-2045(09)70030-0

10.3390/ph3041122

Serrano D , LazzeroniM, ZambonCF et al.: Efficacy of tamoxifen based on cytochrome p450 2D6, CYP2C19 and SULT1A1 genotype in the italian tamoxifen prevention trial.Pharmacogenomics J. (2010) (Epub ahead of print).

Berns P KokM SweepF et al.: CYP-2C19*2 predicts favorable outcome of tamoxifen treatment for advanced breast cancer. 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium (2009).

10.1007/s002280100359

10.1007/s00228-008-0538-y

10.1007/s10654-009-9386-z

10.1007/s10654-007-9199-x

10.1007/BF00145007

10.1007/s10654-010-9451-7

10.1038/tpj.2008.7

10.1007/s10549-008-0076-4

10.1200/JCO.2009.25.0894

10.1001/archsurg.1987.01400230089016

WHO international statistical classification of diseases and related health problems 10th revision (1992) www.who.int/classifications/icd/en

Thông tin
Thông tin xuất bản

Pharmacogenomics

Tập 11 Số 10

1367-1375

Thông tin tác giả